Elevance Health, Inc. ELV

Elevance Health, Inc. es una empresa de beneficios de salud. La compañía opera a través de cuatro segmentos: Negocios Comerciales y Especializados, Negocios Gubernamentales, IngenioRx y Otros. Ofrece una variedad de planes de atención administrada basados en redes para mercados de empleadores grandes y pequeños, individuos, Medicaid y Medicare. Sus planes de atención administrada incluyen organizaciones de proveedores preferidos; organizaciones de mantenimiento de la salud; planes de punto de servicio; planes de indemnización y otros planes híbridos, incluidos los planes de salud impulsados por el consumidor; y productos de solo hospital y beneficios limitados. También proporciona una variedad de servicios de atención administrada a clientes autofinanciados, incluido el procesamiento de reclamaciones, suscripción, seguro de exceso de pérdida, servicios actuariales, acceso a redes de proveedores, gestión de costos médicos, gestión de enfermedades, programas de bienestar y otros servicios administrativos. Ofrece una variedad de productos y servicios de seguros especializados y otros, como beneficios de seguros dentales, de visión, de vida y de discapacidad y gestión de beneficios de radiología.

Con 3 acciones de ELV (USD 1.174,72) habrías recibido USD 20,61 en dividendos en los últimos 12 meses.

• Zacks Investment Research 2 oct

  Are Medical Stocks Lagging Elevance Health, Inc. (ELV) This Year?

  Elevance Health (ELV) has gained 8.9% year-to-date, outperforming the Medical group's 0.2% average gain, with a Zacks Rank #2 (Buy) rating and improving analyst sentiment. American Well Corporation (AMWL) has significantly outperformed with a 161.1% year-to-date return and also holds a Zacks Rank #2 (Buy) rating with increased consensus EPS estimates.

  

• GlobeNewswire Inc. 25 sept

  The American Journal of Managed Care® announces Aaron L. Schwartz, M.D., Ph.D., as 2026 Emerging Leader in Managed Care Research Award recipient

  Dr. Aaron L. Schwartz, an assistant professor at the University of Pennsylvania, has been awarded the 2026 AJMC Seema S. Sonnad Emerging Leader in Managed Care Research Award for his groundbreaking work on low-value care metrics and prior authorization research. His claims-based measures have been adopted by CMS for accountable care programs, and his research has influenced policy decisions at major healthcare organizations and government agencies.

  

• Zacks Investment Research 22 sept

  How Centene's Strong Cash Flow Is Reshaping Its Balance Sheet

  Centene Corporation has significantly improved its financial position by generating nearly $8 billion in operating cash flow in the first half of 2026 and reducing its debt-to-capital ratio to 41.6% through $1.3 billion in senior note repurchases. The company monetized $1 billion in Part D receivables to support debt reduction while maintaining financial flexibility amid Medicaid payment timing swings.

  

• Zacks Investment Research 15 sept

  ELV or DHR: Which Is the Better Value Stock Right Now?

  In a comparison of two Medical Services stocks, Elevance Health (ELV) emerges as the superior value option over Danaher (DHR). ELV holds a Zacks Rank of #2 (Buy) with a Value grade of A, featuring a forward P/E of 15.70 and PEG ratio of 2.22. DHR has a Zacks Rank of #3 (Hold) with a Value grade of D, with a forward P/E of 23.84 and PEG ratio of 2.53. Based on valuation metrics and earnings outlook, ELV is positioned as the better value investment.

  

• Zacks Investment Research 15 sept

  Here's How CVS' Health Services Arm Is Positioned for Long-Term Growth

  CVS Health's Health Services segment demonstrated strong Q2 2026 performance with revenues rising 11.5% to $51.8B and adjusted operating income climbing 10%. Health Care Delivery revenues jumped nearly 23% driven by Oak Street Health, while Pharmacy Services benefited from favorable drug mix and strong new sales of $6B. The company maintained its full-year 2026 outlook despite 340B program adjustments.